Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused...
Day: May 14, 2024
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients...
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used...
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive...
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission...
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data...
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
The Company has also completed the GMP validation work allowing for the release of both MDMA dosage formatsVANCOUVER, British Columbia,...
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux...
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing...
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite...
HealthEquity Closes Acquisition of BenefitWallet HSA Portfolio
Welcomes clients and members to its best-in-class platformDRAPER, Utah, May 14, 2024 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY) ("HealthEquity"),...
Tavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion Therapeutics
Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compoundsDURHAM, N.C.,...
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members...
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ETLITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos...